| scholarly article | Q13442814 |
| P2093 | author name string | X Yang | |
| A T Ferguson | |||
| W G Nelson | |||
| J G Herman | |||
| N E Davidson | |||
| D L Phillips | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 7025-7029 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells | |
| P478 | volume | 61 |
| Q33872756 | (--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. |
| Q33612962 | 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines |
| Q36012225 | A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells |
| Q37656483 | A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy |
| Q35034708 | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer |
| Q36155426 | Aberrant expression and localization of deoxyribonucleic acid methyltransferase 3B in endometriotic stromal cells. |
| Q37354053 | Aberrant promoter CpG methylation and its translational applications in breast cancer. |
| Q30425720 | Acquisition of sexual receptivity: roles of chromatin acetylation, estrogen receptor-alpha, and ovarian hormones |
| Q37141408 | Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy |
| Q35043020 | Aromatase inhibitors and xenograft studies |
| Q34589121 | Aromatase resistance mechanisms in model systems in vivo |
| Q57137315 | Aromatase, aromatase inhibitors, and breast cancer |
| Q28482827 | Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer |
| Q34291226 | Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications |
| Q37031561 | Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer |
| Q37687668 | Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells. |
| Q37901429 | Breast cancer stem cells and their role in resistance to endocrine therapy |
| Q41505907 | CCN5/WISP-2 restores ER-∝ in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen |
| Q33529488 | Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation |
| Q37344785 | Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity |
| Q26798258 | Circadian disruption and breast cancer: an epigenetic link? |
| Q36458731 | Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. |
| Q90431602 | Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells |
| Q30436675 | DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma |
| Q34325308 | Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases |
| Q34693969 | Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression |
| Q34312649 | Differentiation of murine embryonic stem cells induces progesterone receptor gene expression |
| Q38656581 | Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression |
| Q36898831 | Dynamic histone H3 acetylation and methylation at human cytomegalovirus promoters during replication in fibroblasts |
| Q36762940 | Dynamic regulation of estrogen receptor-alpha gene expression in the brain: a role for promoter methylation? |
| Q40014619 | ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor |
| Q37407136 | ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers |
| Q90222199 | ERα is required for suppressing OCT4-induced proliferation of breast cancer cells via DNMT1/ISL1/ERK axis |
| Q64974925 | Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. |
| Q38741783 | Entinostat: a promising treatment option for patients with advanced breast cancer |
| Q34793432 | Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy. |
| Q35668617 | Epigenetic Regulation by Sulforaphane: Opportunities for Breast and Prostate Cancer Chemoprevention |
| Q34859510 | Epigenetic Silencing of Somatostatin in Gastric Cancer |
| Q36337694 | Epigenetic Therapy in Breast Cancer |
| Q33585930 | Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer |
| Q37328845 | Epigenetic alterations in human prostate cancers. |
| Q36334655 | Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells |
| Q36286662 | Epigenetic mechanisms in commonly occurring cancers. |
| Q36624258 | Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer |
| Q37462347 | Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells |
| Q38824324 | Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q47970401 | Epigenetic regulation of estrogen receptor α contributes to age-related differences in transcription across the hippocampal regions CA1 and CA3. |
| Q36891892 | Epigenetic regulation of estrogen signaling in breast cancer |
| Q36836202 | Epigenetic regulation of the estrogen receptor alpha promoter in the cerebral cortex following ischemia in male and female rats |
| Q42730244 | Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme |
| Q36856318 | Epigenetic targeting in breast cancer: therapeutic impact and future direction |
| Q36449057 | Epigenetics as a therapeutic target in breast cancer |
| Q38825290 | Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds |
| Q37078784 | Epigenomics and breast cancer |
| Q37250659 | Estrogen Regulation of MicroRNA Expression |
| Q35951292 | Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers |
| Q33797076 | Estrogen receptor-alpha methylation predicts melanoma progression |
| Q42489213 | Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women |
| Q37690414 | Expression of Estrogen Receptor Alpha in Malignant Melanoma |
| Q34779627 | Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast |
| Q36178606 | Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues |
| Q37515474 | Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway |
| Q34789970 | Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole |
| Q34651821 | Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells |
| Q37295706 | Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients |
| Q49496829 | Genistein and Trichostatin A Induction of Estrogen Receptor Alpha Gene Expression, Apoptosis and Cell Growth Inhibition in Hepatocellular Carcinoma HepG 2 Cells |
| Q47437905 | Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer |
| Q33972354 | Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics |
| Q26775413 | Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? |
| Q34488424 | Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. |
| Q24535587 | Histone deacetylases (HDACs): characterization of the classical HDAC family |
| Q31109027 | Identification of a robust gene signature that predicts breast cancer outcome in independent data sets |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q35990736 | Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells |
| Q39675513 | Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure |
| Q24657263 | Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure |
| Q35088057 | Loss of expression of type IV collagen alpha5 and alpha6 chains in colorectal cancer associated with the hypermethylation of their promoter region |
| Q37520354 | Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells |
| Q35719862 | MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence |
| Q34417159 | Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? |
| Q27001260 | Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer |
| Q58718563 | Mechanisms for estrogen receptor expression in human cancer |
| Q38439266 | Mechanisms of aromatase inhibitor resistance. |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q92935147 | Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer |
| Q24645663 | MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer |
| Q34181207 | Molecular and cellular determinants of estrogen receptor alpha expression |
| Q38927386 | Morphologic and molecular changes in the placenta: what we can learn from environmental exposures |
| Q36327621 | Multigenerational and transgenerational effects of endocrine disrupting chemicals: A role for altered epigenetic regulation? |
| Q39225627 | Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells |
| Q39312968 | Neuronal pentraxin II (NPTX2) is frequently down-regulated by promoter hypermethylation in pancreatic cancers |
| Q33727284 | Novel Strategies to Improve the Endocrine Therapy of Breast Cancer |
| Q37644981 | Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. |
| Q42755954 | Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem |
| Q26991867 | Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis |
| Q88184753 | Pig testis extract augments adiponectin expression and secretion through the peroxisome proliferator-activated receptor signaling pathway in 3T3-L1 adipocytes |
| Q35618892 | Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells |
| Q37639114 | Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients |
| Q37503537 | Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action |
| Q35079955 | Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer |
| Q34994744 | Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor |
| Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
| Q64085901 | Regulation of post-translational modification in breast cancer treatment |
| Q37404590 | Resistance to endocrine therapy: are breast cancer stem cells the culprits? |
| Q40266897 | Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes |
| Q92335596 | Reversal of increased mammary tumorigenesis by valproic acid and hydralazine in offspring of dams fed high fat diet during pregnancy |
| Q35833879 | Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines |
| Q24338663 | SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities |
| Q34613797 | Sex, epilepsy, and epigenetics |
| Q33527153 | Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer |
| Q34258435 | Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells |
| Q37688959 | TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors |
| Q26739969 | Tamoxifen Resistance: Emerging Molecular Targets |
| Q36674724 | The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. |
| Q38917972 | The Estrogen Receptor α-Cistrome Beyond Breast Cancer. |
| Q92181246 | The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases |
| Q39014107 | The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells |
| Q37218548 | The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines |
| Q38921268 | The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. |
| Q38381678 | The novel role of miRNAs for tamoxifen resistance in human breast cancer |
| Q21245741 | The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers |
| Q38004744 | The pituitary tumour epigenome: aberrations and prospects for targeted therapy |
| Q37687220 | The role of histone modifications and variants in regulating gene expression in breast cancer. |
| Q34979726 | The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells |
| Q37468213 | The silent estrogen receptor--can we make it speak? |
| Q37157489 | The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha |
| Q41098508 | The zinc-finger transcriptional factor Slug transcriptionally downregulates ERα by recruiting lysine-specific demethylase 1 in human breast cancer |
| Q36216675 | VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription |
| Q47587176 | Wnt/β‑catenin pathway activation and silencing of the APC gene in HPV‑positive human cervical cancer‑derived cells |
| Q33710113 | Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa |
| Q33815885 | ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer |
| Q84310394 | p53 Binds to estrogen receptor 1 promoter in human breast cancer cells |
| Q34533761 | δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer |
Search more.